Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 12/20 | 0.40 |
| ▸ | CA2 | P00918 | 12/20 | 0.40 |
| ▸ | CA12 | O43570 | 6/20 | 0.40 |
| ▸ | CA9 | Q16790 | 6/20 | 0.40 |
| ▸ | CTSS | P25774 | 1/20 | 0.36 |
| ▸ | CTSK | P43235 | 1/20 | 0.36 |
| ▸ | SYK | P43405 | 1/20 | 0.36 |
| ▸ | STK17B | O94768 | 1/20 | 0.36 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.36 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3178780 | 1.00 | MEN1 (0.54) | MEN1GAAKMT2ATDP1MAOA | |
| SCHEMBL3178776 | 1.00 | MEN1 (0.54) | MEN1GAAKMT2ATDP1MAOA | |
| SCHEMBL5068280 | 0.96 | MEN1 (0.49) | MEN1GAAKMT2ATDP1MAOA | |
| SCHEMBL5068283 | 0.96 | MEN1 (0.49) | MEN1GAAKMT2ATDP1MAOA | |
| SCHEMBL5068282 | 0.96 | MEN1 (0.49) | MEN1GAAKMT2ATDP1MAOA | |
| SCHEMBL4852002 | 0.92 | MEN1 (0.46) | MEN1GAAKMT2ATDP1MAOA | |
| SCHEMBL4852021 | 0.92 | MEN1 (0.46) | MEN1GAAKMT2ATDP1MAOA | |
| SCHEMBL4852013 | 0.92 | MEN1 (0.46) | MEN1GAAKMT2ATDP1MAOA | |
| SCHEMBL8076292 | 0.86 | CTSK (0.48) | CA1CA12CTSSCTSK | |
| SCHEMBL6333389 | 0.86 | KDM4E (0.38) | MEN1GAAKMT2ACA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7655643-B2 | Antibacterial macrocycles with substituted biphenyl | AICURIS GMBH & CO. KG (DE) | 2010-02-02 | — | — | US | disclosed |
| US-20080275018-A1 | ANTIBACTERIAL AMIDE-MACROCYCLES V | AICURIS GMBH & CO. KG (DE) | 2008-11-06 | — | — | US | disclosed |
| US-7446102-B2 | Antibacterial amide macrocycles IV | AICURIS GMBH & CO. KG (DE) | 2008-11-04 | — | — | US | disclosed |
| US-20080076745-A1 | ANTIBACTERIAL AMIDE MACROCYCLES IV | AICURIS GMBH & CO. KG (DE) | 2008-03-27 | — | — | US | disclosed |
| US-20070099885-A1 | Antibacterial macrocycles with substituted biphenyl | AICURIS GMBH & CO. KG (DE) | 2007-05-03 | — | — | US | disclosed |
| US-20050256037-A1 | Antibacterial amide macrocyles | BAYER HEALTHCARE AG (DE) | 2005-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076745-A1 | ANTIBACTERIAL AMIDE MACROCYCLES IV | NOD2, AAAS, AADAC | MEN1 2081/4885GAA 342/4885KMT2A 3059/4885 |
| US-20070099885-A1 | Antibacterial macrocycles with substituted biphenyl | NOD2, AHR, BCL2 | MEN1 1957/4885GAA 810/4885KMT2A 3328/4885 |
| US-20050256037-A1 | Antibacterial amide macrocyles | AADAC, PAM, NOD2 | MEN1 1754/4885GAA 522/4885KMT2A 2507/4885 |
| US-20080275018-A1 | ANTIBACTERIAL AMIDE-MACROCYCLES V | ARG1, HRH3, H1-0 | MEN1 1513/4885GAA 3747/4885KMT2A 1254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.